Brady Martz Wealth Solutions LLC Acquires Shares of 4,662 Amgen Inc. (NASDAQ:AMGN)

Brady Martz Wealth Solutions LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,662 shares of the medical research company's stock, valued at approximately $1,245,000.

Several other institutional investors have also added to or reduced their stakes in AMGN. Capital Performance Advisors LLP acquired a new stake in Amgen during the third quarter worth approximately $25,000. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen during the 3rd quarter worth $29,000. Hershey Financial Advisers LLC bought a new position in shares of Amgen in the second quarter worth $30,000. Matrix Trust Co acquired a new position in Amgen in the third quarter valued at about $36,000. Finally, Livelsberger Financial Advisory bought a new stake in Amgen during the third quarter worth about $56,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 1.0 %

Amgen stock traded up $2.68 during trading hours on Monday, reaching $272.11. 3,244,015 shares of the company's stock were exchanged, compared to its average volume of 3,140,853. The firm's 50 day simple moving average is $273.95 and its 200 day simple moving average is $307.18. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm has a market capitalization of $146.27 billion, a PE ratio of 34.84, a PEG ratio of 2.68 and a beta of 0.56.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion during the quarter, compared to analysts' expectations of $8.50 billion. During the same quarter last year, the firm posted $4.96 earnings per share. The firm's revenue was up 23.2% on a year-over-year basis. Research analysts predict that Amgen Inc. will post 19.57 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.50%. Amgen's dividend payout ratio is currently 121.90%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Redburn Partners decreased their target price on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Wells Fargo & Company reduced their price objective on Amgen from $335.00 to $280.00 and set an "equal weight" rating on the stock in a research note on Friday, January 10th. Bank of America reissued an "underperform" rating and set a $256.00 target price on shares of Amgen in a research note on Tuesday, December 10th. Sanford C. Bernstein started coverage on shares of Amgen in a research note on Thursday, October 17th. They issued an "outperform" rating and a $380.00 price target on the stock. Finally, Barclays upped their price objective on shares of Amgen from $300.00 to $315.00 and gave the stock an "equal weight" rating in a research report on Monday, October 7th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $314.91.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.